Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available SSRIs and SNRIs, which create significant market access hurdles for branded therapies attempting to enter this space. As a result, brand-only drugs (e.g., Trintellix, Rexulti, Vraylar, Auvelity, Spravato, and Caplyta) largely compete for use in treatment-refractory patients. Despite these options, a substantial proportion of patients fail to achieve adequate symptom control with early-line therapies. This unmet need is driving interest in emerging mechanisms—including J&J’s seltorexant, Neurocrine’s osavampator, and Xenon’s azetukalner—as well as psychedelicbased approaches such as COMP360 (COMPASS Pathways), which may reshape future treatment paradigms. Although the broad availability of generics has increased payers’ leverage in managing MDD treatment costs, manufacturers must understand how evolving clinical metrics and valueformoney considerations will shape future market access and prescribing dynamics.
QUESTIONS ANSWERED
- What is the coverage status of branded drugs on commercial plans? What are the common utilization management strategies that payers use?
- How do payer policies affect the prescribing of branded oral atypical antipsychotics (e.g., Rexulti, Vraylar, Caplyta) and NMDA receptor antagonists (Auvelity, Spravato) in this genericized market?
- How do psychiatrists anticipate positioning emerging therapies (e.g., seltorexant, COMP360, osavampator, azetukalner) within the current MDD treatment algorithm?
- How do payers plan to assess and reimburse COMP360 psilocybin (psychedelic) for treatment-resistant depression (TRD), and how might restrictions affect psychiatrist prescribing?
CONTENT HIGHLIGHTS
- Geography: United States
- Primary research: Survey of 100 U.S. psychiatrists, survey of 30 U.S. MCO PDs / MDs
- Fingertip formulary: Formulary coverage and restrictions data for MDD therapies by commercial plans covering approximately 164.3 million lives nationally.
- Real-world data: U.S. pharmacy and medical claims data
- Key drugs covered: Trintellix, Spravato, Auvelity, Rexulti, Vraylar, Caplyta, COMP360, seltorexant, osavampator, azetukalner
KEY ANALYSES
- Reimbursement and contracting
- Access and prescribing
- Buy-and-bill calculations and analysis
- Couponing and patient affordability
- Opportunities and challenges for emerging therapies
PRODUCT DESCRIPTION
Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:
- Identify and learn how to overcome roadblocks to market access to best position your brand.
- Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
- Evaluate competitor strategies for securing favorable market access terms.
